1. Hou W, Hao Y, Yang W, Tian T, Fang P, Du Y, Gao L, Gao Y*, Zhang Q*.The Jieduan-Niwan (JDNW) Formula Ameliorates Hepatocyte Apoptosis: A Study of the Inhibition of E2F1-Mediated Apoptosis Signaling Pathways in Acute-on-Chronic Liver Failure (ACLF) Using Rats.Drug Des Devel Ther.2021.PMID: 34526765.3845-3862.SCI |
2. Cui FQ, Gao YB#, Wang YF*, Meng Y, Cai Z, Shen C, Jiang XC, Zhao WJ.Effect of Tang-Shen-Ning decoction on podocyte epithelial-esenchymal transformation via inhibiting Wnt/β-catenin pathway in diabetic mice.Ann Palliat Med.2021.10(12).12921-12936.SCI |
3. LIANG J, HE J, GAO Y*, Zhu Z* . Exploring the Potential Mechanism of Tang-Shen-Ning Decoction against Diabetic Nephropathy Based on the Combination of Network Pharmacology and Experimental Validation.Evid Based Complement Alternat Med.2021.PMID:34539795.1025053.SCI |
4. Hou W, Wei X, Liang J, Fang P, Ma C, Zhang Q*, Gao Y*.HMGB1-Induced Hepatocyte Pyroptosis Expanding Inflammatory Responses Contributes to the Pathogenesis of Acute-on-Chronic Liver Failure (ACLF).Inflamm Res.2021.PMID: 34992418.7295-7313.SCI |
5. Shi Y, Gao Y*, Wang T, Wang X, He J, Xu J, Wu B, Li Y.Ginsenoside Rg1 Alleviates Podocyte EMT Passage by Regulating AKT/GSK3 β/β-Catenin Pathway by Restoring Autophagic Activity.Evidence-Based Complementary and Alternative Medicine.2020. PMID: 32082395.1903627.SCI |
6. Wang T, Gao Y*, Yue R, Wang X, Shi Y, Xu J, Wu B, Li Y.Ginsenoside Rg1 Alleviates Podocyte Injury Induced by Hyperlipidemia via Targeting the mTOR/NF-κB/NLRP3 Axis.Evidence-Based Complementary and Alternative Medicine.2020.PMID: 33133213.2735714.SCI |
7. Tian N, Gao Y*, Wang X, Wu X, Zou D, Zhu Z, Han Z, Wang T, Shi Y. Emodin mitigates podocytes apoptosis induced by endoplasmic reticulum stress through the inhibition of the PERK pathway in diabetic nephropathy.Drug design, development and therapy .2018. 12.2195-2211.SCI |
8. Wang X, Gao Y*, Tian N, Zhu Z, Wang T, Xu J, Wu B, Zhang N.Astragaloside IV represses high glucose-induced mesangial cells activation by enhancing autophagy via SIRT1 deacetylation of NF-κB P65 subunit.Drug design, development and therapy.2018.12.2971-2980.SCI |
9. Wu X M, Gao Y B*, Xu L P, et al.Tongxinluo Inhibits Renal Fibrosis in Diabetic Nephropathy: Involvement of the Suppression of Intercellular Transfer of TGF-β1-Containing Exosomes from GECs to GMCs. American Journal of Chinese Medicine,.2017.45(5).1-11.SCI |
10. Wang J, Gao Y#, Duan L, et al .Metformin ameliorates skeletal muscle insulin resistance by inhibiting miR-21 expression in a high-fat dietary rat model.Oncotarget.2017.8(58).98029-98039.SCI |
11. Wu X, Gao Y*, Xu L, et al.Exosomes from high glucose-treated glomerular endothelial cells trigger the epithelial-mesenchymal transition and dysfunction of podocytes.Scientific Reports.2017.7(1).7371.SCI |
12. Cui F, Gao Y*, Zhao W, et a. Effect of Tongxinluo on Podocyte Apoptosis via Inhibition of Oxidative Stress and P38 Pathway in Diabetic Rats.Evid Based Complement Alternat Med, .2016.2016(7).5957423.SCI |
13. Wu XM, Gao YB*, Cui FQ, Zhang N.Exosomes from High Glucose-Treated Glomerular Endothelial Cells Activate Mesangial Cells to Promote Renal Fibrosis.Biol Open.2016.5(4).484-491.SCI |
14. Fangqiang Cui, Dawei Zou, Yanbin Gao*, Na Zhang, JinyangWang, Liping Xu, Jianguo Geng, Jiaoyang Li, Shengnan Zhou, Xinyao Wang.Effect of Tongxinluo on Nephrin Expression via Inhibition of Notch1/Snail Pathway in Diabetic Rats.Evidence-Based Complementary and Alternative Medicine.2015.ID 424193.1-11.SCI |
15. Na Zhang, Yanbin Gao*, Dawei Zou, JinyangWang, Jiaoyang Li, Shengnan Zhou, Zhiyao Zhu, Xuan Zhao, Liping Xu, Haiyan Zhang.Effects of Chinese Medicine Tong xinluo on Diabetic Nephropathy via Inhibiting TGF-beta1-Induced Epithelial-to-Mesenchymal Transition.Evidence-Based Complementary and Alternative Medicine.2014.ID 123497.1-12.SCI |
16. Wang JY, Gao YB*, Zhang N, Zou DW, Xu LP, Zhu ZY, Li JY, Zhou SN, Cui FQ, Zeng XJ, Geng JG, Yang JK.. Tongxinluo ameliorates renal structure and function by regulating miR-21-induced epithelial-to-mesenchymal transition in diabetic nephropathy.Am J Physiol Renal Physiol.2014.306(5).F486-95.SCI |
17. Wang JY, Gao YB*, Zhang N, Zou DW, Wang P, Zhu ZY, Li JY, Zhou SN, Wang SC, Wang YY, Yang JK.miR-21 overexpression enhances TGF-β1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol Cell Endocrinol.2014.392(1-2).163-72.SCI |
18. 高彦彬*,赵慧玲.院校教育与师承教育相结合是培养高质量中医人才的有效途径.世界中医药.2013.8(2).138-142.核心期刊 |
19. Da-Wei Zou, Yan-Bin Gao*, Zhi-Yao Zhu, Hui Zhou, Tao-Jing Zhang, Bu-Man Li, Jin-Yang Wang, Min-Zhou Li, Ming-FeiMa, Na Zhang.Traditional Chinese Medicine Tang-Luo-Ning Ameliorates Sciatic Nerve Injuries in Streptozotocin-Induced Diabetic Rats.Evidence-Based Complementary and Alternative Medicine.2013.ID 989670.1-12.SCI |
20. Gao Y*, Zhou H, Zhao H, Feng X, Feng J, Li Y, Zhang H, Lu H, Qian Q, Yu X, Zhang N, Yu J, Ni Q, Pan M.Clinical research of traditional chinese medical intervention on impaired glucose tolerance. Am J Chin Med.2013.41(1).21-32.SCI |
21. 邹大威,高彦彬*,朱智耀,李敏州,马鸣飞,李步满,李勤,王金羊,赵轩.糖络宁对糖尿病大鼠坐骨神经抗氧化酶基因表达的影响.中国实验方剂学杂志.2013.19(1).154-157.核心期刊 |
22. Wang J, Gao Y,*, Ma M, et al..Effect of miR-21 on Renal Fibrosis by Regulating MMP-9 and TIMP1 in kk-ay Diabetic Nephropathy Mice..Cell Biochem Biophys. .2013.2(13).1-10.SCI |
23. 李敏州,高彦彬*,马鸣飞,朱智耀,邹大威,李勤.糖尿病肾病发病机制研究进展 .中国实验方剂学杂志.2012.18(22).366-371.核心期刊 |
24. 李勤,高彦彬*.高彦彬教授治疗糖尿病视网膜病变经验拾荟.中华中医药杂志.2012.27(11).2857-2859.核心期刊 |
25. 朱智耀,高彦彬*,邹大威,李步满,彭继升.糖络宁对糖尿病大鼠背根神经节细胞凋亡的影响.中国中医基础医学杂志.2012.8(6).616-619.核心期刊 |
26. 邹大威,朱智耀,高彦彬*.糖络宁对糖尿病大鼠坐骨神经氧化应激及超微结构的影响.中华中医药杂志.2012.27(5).1253--1256 .核心期刊 |
27. 卢伟,高彦彬 * .糖尿病伴发抑郁症的临床证治体会.中华中医药学刊.2012.(5).68.核心期刊 |
28. 李敏州,高彦彬*,马明飞,王金羊.芪卫颗粒对自发性2 型糖尿病KK_AY小鼠肾组织转化生长因子β1蛋白及mRNA表达的影响.中国中西医结合杂志.2012.32(12).1694-1696.核心期刊 |
29. 邹大威,朱智耀,高彦彬*.糖络宁对糖尿病大鼠坐骨神经氧化应激及超微结构的影响.中华中医药杂志.2012.27(5).1253--1256 .核心期刊 |
30. 朱智耀,高彦彬*,邹大威, 李敏州.从络病学说论治糖尿病周围神经病变.中华中医药学刊.2012.30(4).702-703.核心期刊 |
31. 周晖;高彦彬*;李丽;赵迪;张涛静;夏晶;周焰实.糖脂平对胰岛素抵抗大鼠血清肿瘤坏死因子-α水平及其脂肪组织mRNA表达的影响.中国中医药信息杂志.2012.07(14).702-703.核心期刊 |
32. 李步满,高彦彬*.中药芪卫颗粒对糖尿病大鼠肾脏氧化应激及病理形态的影响. .中国中西医结合肾病杂志.2011.:12(1).20-22..核心期刊 |
33. 夏晶,高彦彬*.益气养阴、化痰逐瘀法治疗早期糖尿病肾病临床研究.安徽中医学院学报.2010.:29(2).22-24.核心期刊 |
34. 李敏州,高彦彬*.黄芪生脉散治疗糖尿病冠心病临床观察.疑难病杂志.2010.:9(9).676-678.核心期刊 |
35. 高彦彬*,张涛静,赵迪.糖络宁对STZ诱导糖尿病大鼠坐骨神经传导速度及病理学影响.中华中医药杂志.2009.24(8).1010-1013.核心期刊 |
36. 林长青,高彦彬*,刘桂芳.糖脂平胶囊对胰岛素抵抗大鼠脂联素表达的影响.陕西中医.2009.5.617-619.核心期刊 |
37. 张涛静,高彦彬*,赵迪.糖络宁对链脲佐菌素诱导糖尿病大鼠的血糖及冷、热刺激反应的影响.北京中医药大学学报.2009.32(5).45-47.核心期刊 |
38. 高彦彬*,张涛静,赵迪.糖络宁对STZ诱导糖尿病大鼠血清粘附因子的影响.中华中医药杂志.2009.24(7).843-845.核心期刊 |
39. 高彦彬*.糖尿病肾病的中医治疗.北京中医药大学学报.2009.16(10).46-48.核心期刊 |
40. 刘桂芳,高彦彬*,林长青.糖脂平对胰岛素抵抗大鼠糖脂代谢的影响.实用中医内科杂志.2009.23(5).7-8.核心期刊 |
41. 刘桂芳,高彦彬*,林长青.糖脂平对胰岛素抵抗大鼠脂肪组织PPARr2 mRNA表达的影响.吉林中医药.2009.3.253-256.核心期刊 |
42. 高彦彬*,林长青.论《伤寒论》保胃气学术思想及其在消渴病中的应用.北京中医药大学学报.2009.32(8).509-512.核心期刊 |
43. 高彦彬*,刘铜华.止消通脉宁治疗糖尿病肾病的研究.中国科技成果杂志.2008.6(5).51.核心期刊 |
44. 高彦彬*.络病与糖尿病慢性并发症.北京中医药大学学报.2008.30(3).62-65.核心期刊 |
45. 高彦彬*,赵慧玲,周 晖.糖肾宁治疗糖尿病肾病的研究.中华中医药杂志.2006.21(7).409-411.核心期刊 |
46. 高彦彬*,周 晖,关 崧.糖脂平治疗糖耐量低减的临床研究.北京中医药大学学报.2006.30(12).846-849.核心期刊 |